Cardiac inotropes: current agents and future directions (Q37851240)

24 August 2017

1 reference

title

Cardiac inotropes: current agents and future directions (English)

1 reference

24 August 2017

Gerd Hasenfuss

1 reference

24 August 2017

John R Teerlink

1 reference

24 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21388993

26 November 2024

publication date

8 March 2011

1 reference

full work available at URL

24 August 2017

published in

European Heart Journal

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

1838-1845

1 reference

New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

The effect of cardiac resynchronization on morbidity and mortality in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Calcium cycling and signaling in cardiac myocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Myosin ATP turnover rate is a mechanism involved in thermogenesis in resting skeletal muscle fibers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Calcium cycling in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Vasodilating mechanisms of levosimendan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Istaroxime: a new luso-inotropic agent for heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

The way things move: looking under the hood of molecular motor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

A novel approach to improve cardiac performance: cardiac myosin activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Overexpression of FK506-binding protein FKBP12.6 in cardiomyocytes reduces ryanodine receptor-mediated Ca(2+) leak from the sarcoplasmic reticulum and increases contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Targeted gene transfer increases contractility and decreases oxygen cost of contractility in normal rat hearts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Nitroxyl (HNO): the Cinderella of the nitric oxide story

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Positive inotropic and lusitropic effects of HNO/NO − in failing hearts: Independence from β-adrenergic signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca2+ cycling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Nitroxyl activates SERCA in cardiac myocytes via glutathiolation of cysteine 674.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

K201 improves aspects of the contractile performance of human failing myocardium via reduction in Ca2+ leak from the sarcoplasmic reticulum

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Energy metabolism in heart failure and remodelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

The metabolic modulators, Etomoxir and NVP-LAB121, fail to reverse pressure overload induced heart failure in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Influence of pyruvate on contractile performance and Ca(2+) cycling in isolated failing human myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Improved systolic and diastolic myocardial function with intracoronary pyruvate in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR026

Existence of the Frank-Starling mechanism in the failing human heart. Investigations on the organ, tissue, and sarcomere levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHR026

Modulation of sarcoplasmic reticulum function by Na+/K+ pump inhibitors with different toxicity: digoxin and PST2744 [(E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride].

26 November 2024

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHR026

Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure

26 November 2024

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHR026

26 November 2024

763

2006

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHR026

26 November 2024

2008

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHR026

26 November 2024

S67

2009

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHR026

26 November 2024

S73

2009

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHR026

26 November 2024

Identifiers

1 reference

24 August 2017

1 reference